WorldWideScience

Sample records for amipaque

  1. Myelography with Amipaque in infants and children

    International Nuclear Information System (INIS)

    The non-ionic water-soluble contrast medium Amipaque (metrizamide) shows a lowered neutrotoxicity, and therefore it may be used in the entire spinal canal. The better visibility of fine strucutres compared with oily and gaseous contrast media allows an excellent diagnostic approach to all spinal affections. Our technique of myelography is described and typical examples are given. (orig.)

  2. Complications after lumbar myelography with amipaque

    International Nuclear Information System (INIS)

    Amipaque is a water soluble, non-ionic myelographic contrast media, and owing to its high diagnostic accuracy and safety, its use is gradually increasing. The authors studied the complication after amipaque lumber myelography in 61 patients with low back pain during the period from January 1981 to November 1981 in Chung Ang University Hospital. The results were as follows: 1. Total complication rate was 52% (32 of 61)and there was no sexual difference in its occurrence. 2. In total, no difference in complication rate was found between head-up positioned group with a degree of 30 .deg. (group I) after procedure and head-up positioned group with a degree of 70 .deg. (group II) but female patients had more complication rate in group I than in group II (75% vs 50%). Headache was more common in group I and nausea was more common in group II. 3. Headache was most common complication (44%) and there was no sexual difference in its occurrence. 4. No significance difference in complication rate was found between patients proved to have HNP and patients to have not. 5. Complications were less common in patients with punctured level of L4-5 than in patients with L2-3or L3-4 level punture

  3. A randomized blind trial of iopamidol (niopam) and metrizamide (amipaque) in lumber radiculography

    International Nuclear Information System (INIS)

    A randomised blind trial comparing Iopamidol (Niopam) and Metrizamide (Amipaque) for lumbar radiculography was performed in 100 patients. Significantly more patients receiving Metrizamide complained of having severe headaches (P<0.05) and vomiting (P<0.05). There was no difference in quality of the radiculograms. (orig.)

  4. The use of metrizamide (amipaque) to visualise the gastrointestinal tract in children

    International Nuclear Information System (INIS)

    Metrizamide (amipaque) has not been used previously as a diagnostic contrast agent in the gastrointestinal tract. Metrizamide is a water-soluble isotonic contrast material having many advantages over barium and existing hypertonic water-soluble agents. There are many clinical situations in children in which metrizamide should be the contrast agent of choice for investigating the gastrointestinal tract. Four neonates are presented in whom barium or gastrografin were absolutely contraindicated. In each case metrizamide gave excellent visualisation of the gastrointestinal tract. It could be followed through the bowel giving excellent visualisation even up to 120h after ingestion. No harmful effects were noted in the four cases studied. (author)

  5. The diameters of the cervical spinal cord shown by Amipaque-myelography

    International Nuclear Information System (INIS)

    The sagittal and cross diameters of the cervical spinal cord were measured in 53 patients with cervical nerve root compression and with no evidence of spinal cord involvement, as well as in 45 patients with spastic tetraparesis and no localised space occupying lesion, and 29 patients with myelographically proven cervical myelography. The true diameters were calculated by the known magnification factor (1:1,4). Patients with spastic tetraparesis showed diameters in normal ranges, as well as widened or diminished sizes of the cord. Some of the patients with cervical myelopathy showed diminished diameters in the caudal parts. This may be a hint for a poor outcome after decompression operation. (orig.)

  6. Contrast myelography in the diagnosis of hernal protrusion of intervertebral disks in lumbar osteochondrosis

    International Nuclear Information System (INIS)

    The paper is concerned with the results of a radiopaque study of the vertebral canal in 701 patients with lumbar osteochondrosis (pneumomyelography was performed in 280, positive myelography with water soluble contrast substances in 421 patients). Myelography using Amipaque, a water soluble contrast substance, is a highly informative method of diagnosis of protrusion of disks. Amipaque is more physiological and sparing as compared to the air and emulsive contrast agents. The combination of myelography with functional X-ray investigations, and tomography permits the detection in most of the cases of protrusion of intervertebral disks. This combination is also used to determine the side of lateral hernias for a less traumatic surgical access. Diagnostic accuracy in positive myelography was 96.5%, in negative myelography 89.13%

  7. Iohexol 300 mg I/ml versus Iopamidol 300 mg I/ml for cervical myelography double blind trial

    International Nuclear Information System (INIS)

    Omnipaque (Iohexol) is the 2nd non-ionic contrast medium developed and marketed by Nycomed AS, Oslo. Experimental studies have shown that the toxicological and pharmacological properties of Omnipaque are closely related to those of Amipaque. However, when administered intrathecally, Omnipaque has less excitative and depressive effect upon the cerebral nervous system than Amipaque. Iopamidol is another 2nd generation non ionic monomeric contrast agent. It was considered of interest to compare those 2 media in the CNS. The main objective of this phase III trial in cervical myelography was to compare the safety, tolerance and image quality of Iopamidol and Iohexol by monitoring clinical examinations, adverse reactions (with attention to psychological disorders) as well as diagnostic information. (orig./MG)

  8. Diagnosis of sacral perineural cysts by computed tomography.

    Science.gov (United States)

    Tabas, J H; Deeb, Z L

    1986-07-01

    Three cases of sacral perineural cysts associated with chronic low-back pain are described with their myelography, computed tomography, and plain film findings. Significant findings include multiple cystic dilatations of lumbosacral nerve root sheaths, enlargement of the sacral foramina by masses isodense with cerebrospinal fluid, and asymmetric epidural fat distribution. Recognition of these findings on unenhanced computed tomography scans should preclude further evaluation by myelography and intrathecal metrizamide (Amipaque) computed tomography. These cysts are usually not the primary cause of back and leg pain. PMID:2942338

  9. Contrast media for radiological examination in gastrointestinal tract leakage

    International Nuclear Information System (INIS)

    The aim of this investigation has been to find a safe and suitable contrast medium (CM) for radiological evaluation of the gastrointestinal tract (GIT) in cases where leakage outside the GIT can be suspected. An experimental study was carried out to evaluate the reactions of various available CM in the bronchi and lungs, mediastinum, pleura and peritoneum of rats. The CM evaluated in the experimental study were, pure barium sulphate (without any additives), commercial barium sulphate (Micropaque, with additives), Dionosil, Hytrast, Gastrografin, Amipaque (in pleura Omnipaque) and Hexabrix. (Auth.)

  10. Comparison of side effects in myelography with iopamidol and metrizamide

    International Nuclear Information System (INIS)

    The study was conducted to compare the side effects in myelography of the two non-ionic water-soluble contrast medias, lopamidol (Niopam) and Metrizamide (Amipaque). A total of 111 patients were examined, 64 with lopamidol and 47 with Metrizamide. Side effects consisted of headache, nausea, vomiting, dizziness, urinary difficulty, muscular pain, seizure, neurobehavioral disturbance, neurological sign change, vital sign change and etc. The common side effects were headache, nausea, vomiting and dizziness in order of frequency. Most of the side effects were subsided within 24 hours following myelography. lopamidol myelography caused fewer and milder side effects than Metrizamide study. The side effects were more commonly observed in cervical, thoracic or total myelography than in lumbar myelography with either lopamidol or Metrizamide. There was no significant correlation between incidence of the side effects and premedication with phenobarbital or valium injection before myelography and CSF sampling during the procedure.

  11. Comparison of side effects in myelography with iopamidol and metrizamide

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Yong; Kang, Heung Sik; Chang, Kee Hyun; Han, Seoul Heui; Kwon, Oh Sung; Myung, Ho Gin [Seoul National University College of Medicine, Seoul (Korea, Republic of)

    1986-12-15

    The study was conducted to compare the side effects in myelography of the two non-ionic water-soluble contrast medias, lopamidol (Niopam) and Metrizamide (Amipaque). A total of 111 patients were examined, 64 with lopamidol and 47 with Metrizamide. Side effects consisted of headache, nausea, vomiting, dizziness, urinary difficulty, muscular pain, seizure, neurobehavioral disturbance, neurological sign change, vital sign change and etc. The common side effects were headache, nausea, vomiting and dizziness in order of frequency. Most of the side effects were subsided within 24 hours following myelography. lopamidol myelography caused fewer and milder side effects than Metrizamide study. The side effects were more commonly observed in cervical, thoracic or total myelography than in lumbar myelography with either lopamidol or Metrizamide. There was no significant correlation between incidence of the side effects and premedication with phenobarbital or valium injection before myelography and CSF sampling during the procedure.

  12. Evaluation of the vascular clinical trial program of metrizamide and iohexol

    International Nuclear Information System (INIS)

    The vascular clinical trial programs of the contrast media metrizamide (Amipaque) and iohexol (Omnipaque), organized by Nyegaard and Co. AS in Northern Europe were assessed and compared. The comparison comprised some selected characteristics of the programs, self-assessment by the investigators involved in both programs (questionnaire) and assessment of the standard of the trial reports (2 evaluators). It was found that Nyegaard clinical research staff spent in average 4 1/2 month for one iohexol trial compared with one month for one of metrizamide. The reason for this was found to be a higher priority, increased regulatory requirements and a uniform data pool established for the iohexol program. In general, a quality improvement was revealed for the iohexol program over the metrizamide program. The 2 evaluators as well as the questioned investigators found the reporting standard of the iohexol trials significantly higher (p<=0.05) than that of the metrizamide trials. (Auth.)

  13. An experimental study on tissue reaction of various contrast agents on mediastinum

    International Nuclear Information System (INIS)

    Till now, there is no consensus about appropriate contrast agents for use in clinical investigation in suspected perforation of the esophagus. Gastrografin, most widely used water soluble contrast agent, is less sensitive in detection of fistulous tract and can induce pulmonary edema, leading to death occasionally, if aspirated. Barium sulphate has been contraindicated without actual evaluation of its effect on mediastinum by experimental and clinical study. The purpose of this experimental study is to evaluate the type of tissue reaction and its severity in mediastinum and, as a result, to propose appropriate contrast agents in various clinical situations of suspected esophageal leakage. Barium sulphate, Hytrat, Gastrografin, Telebrix, Hexabrix, Amipaque, Niopam, and Ultravist were injected into mediastinum of 20 rats in each. The tissue reaction of injection sites were examined microscopically and graded according severity of inflammatory reaction with serial follow up from 1 day to 8 weeks after injection. The results are as follows, 1. Barium sulphate and Hytrast produced highly significant (p<0.01) tissue reaction compared to saline group and early inflammatory reaction was more severe in Hytrast. 2. Water soluble agents produced no significant reaction in mediastinum compared to saline control group and proved to be safe in the situation of leakage into mediastinum. 3. Injected barium caused no death during 8 week follow up in spite of large injected amount and histologically produced localized indolent granuloma after 4 weeks which is expected not to cause any delayed complications. In consideration of above results, superior physical characteristics of barium sulphate and drawbacks of Gastrografin, we concluded as follows. 1. For postoperative assessment of esophageal anastomosis, Barium sulphate is the contrast agent of choice

  14. Torsten Almén (1931-2016): the father of non-ionic iodine contrast media.

    Science.gov (United States)

    Nyman, Ulf; Ekberg, Olle; Aspelin, Peter

    2016-09-01

    The Swedish radiologist Torsten Almén is the first clinical radiologist ever to have made a fundamental contribution to intravascular contrast medium design, the development of non-ionic contrast media. He became emotionally triggered by the patients' severe pain each time he injected the ionic "high-osmolar" contrast media when performing peripheral arteriographies in the early 1960s. One day he got a flash of genius that combined the observation of pain, a pathophysiological theory and how to eliminate it with suitable contrast media chemistry. After self-studies in chemistry he developed the concept of iodine contrast media not dissociating into ions in solution to reduce their osmolality and even reach plasma isotonicity. He offered several pharmaceutical companies his concept of mono- and polymeric non-ionic agents but without response, since it was considered against the chemical laws of that time. Contrast media constructed as salts and dissociating into ions in solution was regarded an absolute necessity to achieve high enough water solubility and concentration for diagnostic purposes. Finally a small Norwegian company, Nyegaard & Co., took up his idea 1968 and together they developed the essentially painless "low-osmolar" monomeric non-ionic metrizamide (Amipaque) released in 1974 and iohexol (Omipaque) in 1982 followed by the "iso-osmolar" dimeric non-ionic iodixanol (Visipaque) released in 1993. This has implied a profound paradigm shift with regard to reduction of both hypertonic and chemotoxic side effects, which have been a prerequisite for the today's widespread use of contrast medium-enhanced CT and advanced endovascular interventional techniques even in fragile patients. PMID:27225455